- Home
- NUVL
NUVL
Nuvalent Inc.
as 07-26-2024 4:00pm EST
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.9B | IPO Year: | 2021 |
| Target Price: | $96.33 | AVG Volume (30 days): | 362.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.86 - $89.39 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Conley Emily | NUVL | Director | Jul 15 '24 | Sell | $79.43 | 700 | $55,601.00 | 6,807 | SEC Form 4 |
| Conley Emily | NUVL | Director | Jul 15 '24 | Sell | $80.29 | 1,900 | $152,551.00 | 4,907 | SEC Form 4 |
| Conley Emily | NUVL | Director | Jul 15 '24 | Sell | $81.40 | 2,195 | $178,673.00 | 2,712 | SEC Form 4 |
| Conley Emily | NUVL | Director | Jul 15 '24 | Sell | $81.93 | 205 | $16,795.65 | 2,507 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jul 12 '24 | Sell | $80.16 | 6,000 | $480,960.00 | 33,300 | SEC Form 4 |
| Noci Darlene | NUVL | Chief Development Officer | Jul 1 '24 | Sell | $75.46 | 4,458 | $336,400.68 | 33,842 | SEC Form 4 |
| Noci Darlene | NUVL | Chief Development Officer | Jul 1 '24 | Sell | $76.19 | 542 | $41,294.98 | 33,300 | SEC Form 4 |
| Balcom Alexandra | NUVL | Chief Financial Officer | Jun 28 '24 | Sell | $75.15 | 7,565 | $568,509.75 | 35,735 | SEC Form 4 |
| Balcom Alexandra | NUVL | Chief Financial Officer | Jun 28 '24 | Sell | $76.19 | 1,863 | $141,941.97 | 33,872 | SEC Form 4 |
| Balcom Alexandra | NUVL | Chief Financial Officer | Jun 28 '24 | Sell | $76.73 | 572 | $43,889.56 | 33,300 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Jun 24 '24 | Sell | $80.98 | 190 | $15,386.20 | 232,522 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Jun 24 '24 | Sell | $80.50 | 1,176 | $94,668.00 | 232,712 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Jun 24 '24 | Sell | $79.47 | 634 | $50,383.98 | 233,888 | SEC Form 4 |
| Conley Emily | NUVL | Director | Jun 14 '24 | Sell | $77.52 | 4,777 | $370,313.04 | 2,730 | SEC Form 4 |
| Conley Emily | NUVL | Director | Jun 14 '24 | Sell | $78.31 | 223 | $17,463.13 | 2,507 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $73.42 | 230 | $16,886.60 | 41,070 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $74.39 | 750 | $55,792.50 | 40,320 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $75.81 | 156 | $11,826.36 | 40,164 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $76.88 | 526 | $40,438.88 | 39,638 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $77.97 | 148 | $11,539.56 | 39,490 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $79.69 | 541 | $43,112.29 | 38,949 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $80.43 | 199 | $16,005.57 | 38,750 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $82.05 | 3,884 | $318,682.20 | 34,866 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jun 6 '24 | Sell | $82.33 | 1,566 | $128,928.78 | 33,300 | SEC Form 4 |
| Shair Matthew | NUVL | Director | May 28 '24 | Sell | $66.87 | 1,256 | $83,988.72 | 235,266 | SEC Form 4 |
Latest Nuvalent Inc. News
NUVL Breaking Stock News: Dive into NUVL Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
4 days ago
Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment
PR Newswire
5 days ago
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
MT Newswires
10 days ago
Nuvalent Insider Sold Shares Worth $403,621, According to a Recent SEC Filing
PR Newswire
11 days ago
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
MT Newswires
15 days ago
Nuvalent Names Henry Pelish Chief Scientific Officer; Shares Rise
PR Newswire
16 days ago
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
MT Newswires
16 days ago
Stifel Adjusts Price Target on Nuvalent to $115 From $103, Maintains Buy Rating
MT Newswires
2 months ago
Nuvalent Insider Sold Shares Worth $643,213, According to a Recent SEC Filing
Compare NUVL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVL Nuvalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.